iBio (NASDAQ: IBIO) substitutes SILV Fund after 876,340‑share transfer

Rhea-AI Filing Summary

iBio, Inc. filed a prospectus supplement updating a resale registration that covers 11,061,738 shares of its common stock. The supplement substitutes SILV Fund Ltd for Point72 Associates, LLC as a selling stockholder following a transfer of 876,340 shares.

The supplement amends the "Selling Stockholders" table to reflect the transfer and shows entities affiliated with Sirenia Capital Management LP beneficially own 11,604,590 shares ( 9.99%). The supplement reiterates the Prospectus terms and states the Nasdaq last sale price was $1.63 on April 28, 2026.

Insights

Capital Markets Counsel

Prospectus supplement records a selling-holder substitution and leaves the resale registration unchanged.

The supplement updates the "Selling Stockholders" table to substitute SILV Fund Ltd for Point72 Associates, LLC after a transfer of 876,340 shares. The underlying resale registration for 11,061,738 shares remains in effect.

Cash‑flow treatment and placement mechanics are not restated here; timing and methods depend on the existing Prospectus. Subsequent resale activity will follow the Prospectus distribution methods and any applicable market rules.

Key Figures

Registered shares: 11,061,738 shares Per‑share price (last): $1.63 Transfer amount: 876,340 shares +2 more

5 metrics

Registered shares 11,061,738 shares Resale registration per Prospectus Supplement No. 1

Per‑share price (last) $1.63 Nasdaq last reported sale price on <date>April 28, 2026</date>

Transfer amount 876,340 shares Transferred from Point72 to SILV Fund Ltd and reflected in table

Sirenia‑affiliated holdings 11,604,590 shares Beneficial ownership shown in Selling Stockholders table

Percentage ownership 9.99% Percentage shown for Sirenia‑affiliated entities

Key Terms

Selling Stockholders, Prospectus Supplement, Rule 424(b)(3)

3 terms

Selling Stockholders regulatory

"update the information in the table appearing under the caption "Selling Stockholders""

Selling stockholders are existing owners of a company's shares who are offering some or all of their holdings for sale, often as part of a public offering or secondary transaction. For investors this matters because such sales increase the number of shares available to buy, can signal how confident current owners are about future prospects, and may put short-term pressure on the stock price similar to more tickets being released for a popular event.

Prospectus Supplement regulatory

"This Prospectus Supplement No. 1 supplements the prospectus dated February 9, 2026"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

Rule 424(b)(3) regulatory

"Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-293085"

Rule 424(b)(3) is a U.S. Securities and Exchange Commission filing rule that governs how updated prospectus information about a securities offering is formally added to an existing registration statement. For investors, seeing a 424(b)(3) filing means the company has officially recorded new offering details – like the number of shares, pricing range or other terms – so it’s a reliable place to check the latest, legally required disclosures; think of it as the official addendum to a product manual that must be filed before the product is sold.

Offering Details

resale/secondary

Offering

Offering Type resale/secondary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/29/2026 - 09:11 AM Learn about SEC filing dates

FAQ

What does iBio's prospectus supplement (IBIO) change?

It substitutes a selling stockholder and updates the resale table. The supplement replaces Point72 with SILV Fund Ltd after a transfer of 876,340 shares, keeping the registered resale amount at 11,061,738 shares under the Prospectus.

How many shares are registered for resale under the prospectus supplement?

11,061,738 shares of common stock are registered for resale. This supplement does not change that aggregate registered amount; it only updates the Selling Stockholders table to reflect a transfer.

Who became a selling stockholder due to the transfer?

SILV Fund Ltd was substituted as a selling stockholder. The substitution follows a transfer of 876,340 shares from Point72 Associates, LLC and is reflected in the updated Selling Stockholders table.

What ownership stake is disclosed for Sirenia‑affiliated entities?

Entities affiliated with Sirenia Capital Management LP are shown with 11,604,590 shares. The table lists that holding as 9.99% beneficial ownership in the excerpt provided.

What was iBio's last reported Nasdaq sale price noted in the supplement?

The supplement cites a Nasdaq last sale price of $1.63 per share. That price is reported as of April 28, 2026 and appears in the supplement for reference.

Filed Pursuant to Rule 424(b)(3)
Registration Statement No. 333- 293085

PROSPECTUS SUPPLEMENT NO. 1

11,061,738 Shares of Common Stock

This Prospectus Supplement No. 1 supplements the prospectus dated February 9, 2026 (the “Prospectus”) relating to the resale from time to time of up to 11,061,738 shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”) of iBio, Inc. (the Company”) by the Selling Stockholders identified in the Prospectus (the “Selling Stockholders”), including their pledgees, assignees, donees, transferees or their respective successors-in-interest.

The purpose of this Prospectus Supplement No. 1 is solely to update the information in the table appearing under the caption “Selling Stockholders” commencing on page 9 of the Prospectus to reflect in the Selling Stockholder table a transfer of 876,340 shares of Common Stock from Point72 Associates, LLC (“Point72”), a selling stockholder previously identified in the Prospectus, to SILV Fund Ltd, another entity which as a result of such transfer is being substituted as a selling stockholder.

Shares of Common Stock Beneficially

Maximum Number of Shares of Common Stock

Shares of Common Stock To Be Beneficially Owned Immediately Following the Sale of the Shares of Common Stock

Owned Prior

Being Offered

Offered for Resale

Selling Stockholders

to the Offering

for Resale

Number

Percentage

Entities affiliated with Sirenia Capital Management LP1)

11,604,590

876,340

6,077,525

9.99

%

(1) The shares reported under “Maximum Number of Shares Being Offered for Resale” consist of the 876,340 shares of Common Stock held by SILV Fund, Ltd. that were previously held by Point72. Sirenia Capital Management LP (“Sirenia”) serves as the investment manager to SILV Fund, Ltd. and, as a result, maintains voting and investment power with respect to the securities held by SILV Fund, Ltd. In addition, Sirenia manages (1) an account (the “Sirenia Managed Account”) that holds (i) August 2025 PFWs exercisable into a total of 7,140,000 shares of Common Stock and (ii) Series G Warrants exercisable into a total of 3,570,000 shares of Common and (2) a separate fund (the “Sirenia Fund”) that holds 18,250 shares of Common Stock.  The Sirenia Managed Account is prohibited from exercising such August 2025 PFWs and Series G Warrants, if, as a result of such exercise, it and any person or entity with which it would aggregate beneficial ownership would beneficially own more than 9.99% of the total number of shares of Common Stock then issued and outstanding immediately after giving effect to the exercise. The forgoing number of shares issuable upon exercise of the August 2025 PFWs and Series G Warrants as well as the shares reported under “Shares of Common Stock Beneficially Owned Prior to the Offering” do not give effect to such limitation on exercisability of the August 2025 PFWs or the Series G Warrants.  Sirenia Capital Management GP LLC (“Sirenia GP”) is the general partner of Sirenia. Alex Silverstein is the managing member of Sirenia GP. Each of SILV Fund, Ltd., the Sirenia Managed Account, the Sirenia Fund, Sirenia GP and Mr. Silverstein disclaims beneficial ownership over such securities.  The address of SILV Fund Ltd. is c/o Sirenia Capital Management LP, 1674 Meridian Avenue, Suite 320, Miami Beach, FL 33139.

All of the other portions of the Prospectus remain unchanged.

 This Prospectus Supplement No. 1 is not complete without, and may not be utilized except in connection with, the Prospectus, including any amendments or supplements thereto. This Prospectus Supplement No. 1 is qualified by reference to the Prospectus, except to the extent that the information provided by this Prospectus Supplement No. 1 supersedes information contained in the Prospectus. Capitalized terms used in this Prospectus Supplement No. 1 and not otherwise defined herein have the meanings specified in the Prospectus.

Our Common Stock is listed on The Nasdaq Capital Market (“Nasdaq”) under the symbol “IBIO.” On April 28, 2026, the last reported sale price of our Common Stock on Nasdaq was $1.63 per share.

An investment in shares of our Common Stock involves risks. See the “Risk Factors” beginning on page 5 of the Prospectus and in our filings with the Securities and Exchange Commission.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prospectus or this Prospectus Supplement No. 1. Any representation to the contrary is a criminal offense.

The date of this Prospectus Supplement No. 1 is April 29, 2026.